Cosmos Health Secures 3-Year, 3.9M-Unit Contract for Progesterone Pessaries
Event summary
- Cosmos Health's Cana Laboratories signs 3-year deal to manufacture 3.9M units of VASCLOR GEST progesterone pessaries for Verisfield.
- Annual production target: 1.3M units (400mg per pessary, 15 per box).
- Expands Cana's contract manufacturing into women's health and reproductive medicine.
- Verisfield markets 60+ pharmaceutical products across seven therapeutic categories.
The big picture
This agreement marks Cosmos Health's push into higher-margin contract manufacturing, particularly in the growing women's health sector. The deal with Verisfield diversifies Cana's customer base and therapeutic focus, aligning with broader industry trends toward specialized reproductive medicine solutions. With its European GMP-certified infrastructure, Cosmos Health is positioning itself as a key player in outsourced pharmaceutical production.
What we're watching
- Revenue Diversification
- How this high-margin contract manufacturing deal will impact Cosmos Health's revenue diversification strategy.
- Capacity Utilization
- Whether Cosmos Health can sustain this production pace while expanding into other therapeutic areas.
- Market Expansion
- The pace at which Cosmos Health can leverage this deal to enter new markets beyond Greece and the UK.
Related topics